Entering an era of radiogenomics in prostate cancer risk stratification

Nachiketh Soodana-Prakash, Radka Stoyanova, Abhishek Bhat, Maria C. Velasquez, Omer E. Kineish, Alan Pollack, Dipen J. Parekh, Sanoj Punnen

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Radiogenomics is a field that amalgamates data from genomics and imaging techniques in order to derive clinically meaningful trends. In this article, we discuss the importance of prostate cancer risk classification and how data derived from genomic testing and multi-parametric magnetic resonance imaging (mpMRI) can be integrated into clinical decision-making processes with a focus on active surveillance (AS). Finally, we describe an ongoing prospective trial (Miami MAST trial) which incorporates imaging (mpMRI) and radiomics data in patients who are on AS for prostate cancer.

Original languageEnglish (US)
Pages (from-to)S443-S452
JournalTranslational Andrology and Urology
StatePublished - Sep 1 2018


  • Genomics assays
  • Personalized information
  • Prostate cancer
  • Radiogenomics
  • Risk stratification

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology


Dive into the research topics of 'Entering an era of radiogenomics in prostate cancer risk stratification'. Together they form a unique fingerprint.

Cite this